🔗 Share this article

As America proceeds with historic adjustments to its immunization recommendations, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by questioning COVID-19 vaccines in the pandemic and has zeroed in on possible fatalities following Covid immunization in her recent position at the FDA.

Proposed Changes to Pediatric Immunization Program

Health officials were set to unveil radical revisions to the pediatric vaccination calendar earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with many the international standard with no evidence for public health gain. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated acting director of the FDA’s CDER, the fifth appointee to run the division this year.

A New Direction at the Agency

This interim role could signify a closer partnership between the drug and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending certain childhood vaccine recommendations in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – usually the domain of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

The appointee has little discernible background in pharmaceutical research, approval processes or leadership, which has been typical for previous heads of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She is not an expert in drug approvals.”

Former heads of the center would “understand legal statutes and the science of drug development”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who headed CBER have had.”

CDER has an immense portfolio at the agency, Woodcock stated.

“Many people just zeroes in on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and all of those must be looked after,” Dr. Woodcock explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a major management aspect to the job, which oversees in excess of 5,000 employees. “It is a enormous leadership role, if you execute it properly,” she concluded.

Response and Controversial Initiatives

When asked about concerns about Høeg’s fitness for the role and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “questions are based on incorrect assumptions”.

“Her resume aligns with the responsibilities of her job,” the representative explained, pointing to the time Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid drug-approval program that allegedly concerned her predecessors. “How are these medications being picked for this fast-track system? Who makes the decisions?” Dr. Howard said. “There is a lot of secrecy occurring at the agency right now.”

Overall, he remarked, “the agency appears to be shifting towards less stringent rules of pharmaceuticals, with the exception of vaccines.”

Public History on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, history, Howard have noted. She released a research paper using non-validated volunteer-provided data to determine the frequency of myocarditis following Covid immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new government featured revising guidelines for recently developed shots and discontinuing “optional” vaccines, she said after the election on a online show. At the agency, Høeg has reportedly floated the idea of barring teenage boys from getting COVID-19 vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and reverse-engineers to fit the data in a extremely disingenuous, untruthful manner,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|